AIM ImmunoTech Inc. (AIM) Financials

AIM Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2024 8.6 million 9.9 million
Sept. 30, 2024 13.6 million 10.7 million
June 30, 2024 15.7 million 9.6 million
March 31, 2024 16.2 million 11.4 million

AIM Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2024 -4.1 million 196000
Sept. 30, 2024 -3.3 million 330000
June 30, 2024 -3.2 million 80000
March 31, 2024 -4.9 million 80000

AIM Net Income

No data available :(

AIM Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2024 4.0 million 395000 634000
Sept. 30, 2024 7.2 million 576000 669000
June 30, 2024 10.1 million 771000 722000
March 31, 2024 10.9 million 1.5 million 777000

AIM Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2024 56.8 million
Sept. 30, 2024 57.7 million
June 30, 2024 52.8 million
March 31, 2024 49.5 million

AIM Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2024 119000 1.7 million 4.2 million -
Sept. 30, 2024 158000 1.4 million 3.1 million -
June 30, 2024 229000 1.1 million 2.6 million 61000
March 31, 2024 50000 2.0 million 3.8 million -58000

AIM Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2024 45000 7000
Sept. 30, 2024 35000 8000
June 30, 2024 50000 8000
March 31, 2024 40000 66000

AIM Revenue by Segment

Graph available only for paid members. Upgrade to see it.

AIM

Price: $0.09

52 week price:
0.03
0.62

Earnings Per Share: -0.31 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 36383

Market Capitalization: 6.5 million

Links: